Study Characteristics.
- Nathan Ford (59436)
- Zara Shubber (279389)
- Andrew Hill (95939)
- Marco Vitoria (183846)
- Meg Doherty (482820)
- Edward J. Mills (34548)
- Andy Gray (482821)
Publication date
November 2013
DOIAbstract
<p>3TC, lamivudine; ATV/r, ritonavir-boosted atazanavir; AZT, zidovudine; ABC, abacavir; d4T, stavudine; DTG, dolutegravir; EFV, efavirenz; FTC, emtricitabine; LPV/r, ritonavir-boosted lopinavir; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI/r, ritonavir-boosted protease inhibitor; RAL, raltegravir; TDF, tenofovir disoproxil fumarate.</p
Add to ORKG